Beamr video compression achieves up to 50% improvement for AVs
Investing.com -- Shares of Portage Biotech Inc. (NASDAQ: PRTG) surged 29% following the presentation of new preclinical data for its mesothelioma treatment, PORT-7. The company unveiled these findings at the European Lung Cancer Congress in Paris, which took place from March 26-29.
Portage Biotech’s recent data indicates that PORT-7, a selective Adenosine A2B receptor inhibitor, not only shows single-agent activity but also achieves over 90% inhibition of tumor growth when used in conjunction with an anti-PD1 antibody in a mesothelioma murine model. Furthermore, the study revealed significant infiltration of immune effector cells in the tumors. Mesothelioma, a particularly aggressive form of cancer with few existing treatment options, could potentially benefit from this novel approach to immunotherapy.
The company is also progressing with the dose escalation of PORT-6, another promising compound designed to inhibit the A2A adenosine receptor. Portage Biotech aims to combine PORT-6 with PORT-7 in a clinical trial to create a comprehensive blockade of adenosine-induced immunosuppression within the tumor microenvironment. This strategy is intended to enhance the immune system’s response to tumors and improve the efficacy of immunotherapy for solid tumors.
The enthusiasm surrounding Portage Biotech’s stock can be attributed to the promising implications of these preclinical results, suggesting a potential advancement in treatment for mesothelioma patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.